{"id":742991,"date":"2023-03-28T07:04:04","date_gmt":"2023-03-28T11:04:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/"},"modified":"2023-03-28T07:04:04","modified_gmt":"2023-03-28T11:04:04","slug":"monopar-to-present-at-the-jefferies-radiopharma-innovation-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/","title":{"rendered":"Monopar to Present at the Jefferies Radiopharma Innovation Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMETTE, Ill., March  28, 2023  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week.<\/p>\n<p>\n        <strong><br \/>\n          <em>Presentation Details:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>Date: April 3, 2023<br \/>Time: 1:00 \u2013 1:30 pm <br \/>Location: Jefferies Conference Center, NYC, New York<\/p>\n<p>\n        <strong>About Monopar Therapeutics Inc.<\/strong>\n      <\/p>\n<p>Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hgNeeYbDO4_au11GY5pF5mobPERmbuwTXRE912eJrrb1NcCBEe9mxMs01rW9mns_H2ZG-uGFISwdmtNBPsgfxlOj5qx3sZd4ClfUOBpjzcU20t8TzuaaERzIRjMkXVFV10u_mDrAWCnEmNxlkopQ4_Pdhg_lG4Drnel45o82sXAacZg0-vn0B_YU6ol3OcAs-2X0Huse4qVSftbarfIDpBm8Su04RZRvnmf-ysYTGwc=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.monopartx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p>\n        <strong>Monopar Therapeutics Inc.<\/strong><br \/>\n        <br \/>Investor Relations<br \/>Kim R. Tsuchimoto<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=23xt_s7-ean2-p5FftcJzfoWdFd7Npb5yaMsPby_r7c8fIUrvyK_mJpd9UeRHMQ0p7Vs5hpYJfBNZ5-_JFUHDiuRzV0bVS9PwyKTBTymjuc=\" rel=\"nofollow noopener\" target=\"_blank\"><u>kimtsu@monopartx.com<\/u><\/a><\/p>\n<p>Follow Monopar on social media for updates:\u2009 <br \/>Twitter: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7ekC8ojFA04Ae_uZrB0d9HlXgz5inD8sGkj-VdDN8hrvHHlfeEJRn7EtyEuVDdx0SEJIekWRhl8AU4tUIW8Vuldo5MDp1X9NeL4TqCnUojlgD_TSab5s2imIl5Z6M6z0kvKhkjJRu-ogoSsKfpu5kWQrIjncFhJLEoLWqn6-gNuaJYgylzboodixr3BV8dvCK7U2QeL-N37J6EPQStTetqBMx7MGjVgjxgWzsxiIuaU=\" rel=\"nofollow noopener\" target=\"_blank\"><u>@MonoparTx<\/u><\/a>\u2009 LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y5QEsdrD5_LR-qS4TFC8JfSoY71kJfRt76U8zglgyiGs1n_Iq2Qo2Smss9PEN-AxqE0kO_IukQF79lU1tq9gSFLc-OpIkqdid0MKxws0ZOMlALRq0zKoVBc7RN2KYdUUnv8bjo8MiCJsQrmJvzeywWSmYdL0V5R81yNco24cKggKsvXP_7Yhjt-M3PLfAqUb99SltbYGx7rtcycJyi3sTEeyg_ucsS8e0QYwKyDVzEdtJcNMMZ-4sGXpikBxMmwZstPK5lrvvQBD4p54NAsvF2I2VU2w2Scs5wvZVImTL07XNNG5Z8fDCctChEnTtred\" rel=\"nofollow noopener\" target=\"_blank\"><u>Monopar Therapeutics<\/u><\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjIwMzdkZDAtNjNhZS00YmQ1LWI1ZDQtY2U4ZDE5ZjJiOTk2LTEyMDU0MTY=\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week. Presentation Details: Date: April 3, 2023Time: 1:00 \u2013 1:30 pm Location: Jefferies Conference Center, NYC, New York About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar to Present at the Jefferies Radiopharma Innovation Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742991","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar to Present at the Jefferies Radiopharma Innovation Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar to Present at the Jefferies Radiopharma Innovation Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week. Presentation Details: Date: April 3, 2023Time: 1:00 \u2013 1:30 pm Location: Jefferies Conference Center, NYC, New York About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, &hellip; Continue reading &quot;Monopar to Present at the Jefferies Radiopharma Innovation Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T11:04:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar to Present at the Jefferies Radiopharma Innovation Summit\",\"datePublished\":\"2023-03-28T11:04:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/\"},\"wordCount\":173,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/\",\"name\":\"Monopar to Present at the Jefferies Radiopharma Innovation Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=\",\"datePublished\":\"2023-03-28T11:04:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar to Present at the Jefferies Radiopharma Innovation Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar to Present at the Jefferies Radiopharma Innovation Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/","og_locale":"en_US","og_type":"article","og_title":"Monopar to Present at the Jefferies Radiopharma Innovation Summit - Market Newsdesk","og_description":"WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week. Presentation Details: Date: April 3, 2023Time: 1:00 \u2013 1:30 pm Location: Jefferies Conference Center, NYC, New York About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, &hellip; Continue reading \"Monopar to Present at the Jefferies Radiopharma Innovation Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T11:04:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar to Present at the Jefferies Radiopharma Innovation Summit","datePublished":"2023-03-28T11:04:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/"},"wordCount":173,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/","name":"Monopar to Present at the Jefferies Radiopharma Innovation Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=","datePublished":"2023-03-28T11:04:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQwMCM1NDk0NDg1IzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar to Present at the Jefferies Radiopharma Innovation Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742991"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742991\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}